Grifols SA ADR (GRFS) - Stock Price & Dividends

Exchange: USA Stocks • Country: Spain • Currency: USD • Type: Common Stock • ISIN: US3984384087

Grifols SA ADR (NASDAQ:GRFS) is a plasma therapeutic company with operations in Spain, the United States, Canada, and internationally.

The company's Biopharma segment specializes in plasma derivatives products, offering a range that includes immune globulin injections, rabies immune globulin, alpha 1-proteinase inhibitor, antihemophilic factor products, albumin solutions, and non-plasma derivative medicinal products like Tavlesse.

In addition to its Biopharma offerings, Grifols also has a Diagnostic segment, providing transfusion medicine systems, blood screening technologies, clinical and diagnostics products, and various analyzers and antigens used in healthcare diagnostics.

The Bio Supplies segment of Grifols provides human biological materials for life sciences research and pharmaceutical and diagnostic product development and manufacturing.

Furthermore, Grifols offers healthcare solutions through its Others segment, which includes services and products used by hospitals, blood banks, plasma collection centers, and other healthcare systems. These solutions encompass parenteral solutions, robotics, and software to support healthcare providers in diagnosing and treating patients with conditions such as hemophilia, immune deficiencies, and infectious diseases.

Grifols has established collaboration agreements with entities like Canadian Blood Services, GIANT, and GigaGen to enhance its product offerings and develop innovative therapies. The company was founded in 1940 and has its headquarters in Barcelona, Spain. For more information, you can visit their website at https://www.grifols.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Grifols SA ADR (GRFS) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Grifols SA ADR (GRFS) - Stock Price & Dividends

GRFS Stock Overview

Market Cap in USD 5,436m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2006-05-17

GRFS Stock Ratings

Fundamental -0.73
Dividend 0.61
Growth 5y -5.16
Rel. Performance vs Sector -3.04
Analysts 4.33/5
Fair Price Momentum 5.41 USD
Fair Price DCF -

GRFS Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y -100.00%
Payout Consistency 59.4%

GRFS Growth Ratios

Growth 12m -7.51%
Growth Correlation 12m 1%
Growth Correlation 3m -37%
CAGR 5y -18.89%
Sharpe Ratio 12m -0.20
Alpha vs SP500 12m -33.38
Beta vs SP500 5y weekly 0.76
ValueRay RSI 40.72
Volatility GJR Garch 1y 118.14%
Price / SMA 50 -10.98%
Price / SMA 200 -26.03%
Current Volume 950k
Average Volume 20d 4171.3k

External Links for GRFS Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of GRFS stocks?
As of March 29, 2024, the stock is trading at USD 6.65 with a total of 950,032 shares traded.
Over the past week, the price has changed by +5.72%, over one month by -28.49%, over three months by -35.31% and over the past year by -5.67%.
What is the forecast for GRFS stock price target?
According to ValueRays Forecast Model, GRFS Grifols SA ADR will be worth about 5.8 in March 2025. The stock is currently trading at 6.65. This means that the stock has a potential downside of -12.18%.
Issuer Forecast Upside
Wallstreet Target Price 15.9 138.8%
Analysts Target Price 16.3 145.3%
ValueRay Target Price 5.8 -12.2%